Compositions and methods for treatment of inflammatory bowel...

Details Compositions and methods for treatment of inflammatory bowel... Compositions and methods for treatment of inflammatory bowel...

2006-10-03

2011-12-20

Spivack, Phyllis G. (Department: 1629)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

08080579

ABSTRACT:
The present invention provides compositions and methods for treating inflammatory bowel disease. In particular, the present invention provides methods of therapeutically treating symptoms of inflammatory bowel disease using compositions comprising an angiotensin converting enzyme (ACE) inhibitor and polyethylene glycol.

REFERENCES:
patent: 4344949 (1982-08-01), Hoefle et al.
patent: 4473575 (1984-09-01), Watthey
patent: 6267990 (2001-07-01), Fischer et al.
patent: 6413494 (2002-07-01), Lee et al.
patent: 2005/0020654 (2005-01-01), Pershadsingh et al.
patent: 2005/0256095 (2005-11-01), Ahlem et al.
patent: 2005/0271596 (2005-12-01), Friedman et al.
patent: 2006/0167012 (2006-07-01), Noble et al.
patent: 79-022 (1982-02-01), None
patent: 60668 (1982-08-01), None
patent: 80822 (1982-11-01), None
patent: 2103614 (1982-08-01), None
Odze, R. “Diagnostic Problems and Advances in Inflammatory Bowel Disease”. Modern Pathology. 2003. vol. 16. No. 4. pp. 347-358.
The Merck Manual, 17th edition (1999), p. 302-307.
Kirsner, J. B., et al. (eds), Inflammatory Bowel Disease, 3rd ed., Lea and Febiger, Philadelphia (1988). This is a book and is not being supplied at this time.
Zipser, R. D., (ed.), “Mediators of Inflammation in Inflammatory Bowel Diseaase”, Dig. Dis. Sci., 33 Suppl.:1S-87S (1988).
Schappi, et al., “Colitis in chronic granulomatous disease” Arch. Dis. Child., 1984:147-151 (2001).
Noguchi, et al., “Comparison of Acute Hemodynamic Effects of MC-838, a New Angiotensin-Converting Enzyme Inhibitor, with Captopril in Anesthetized Dogs”, Jap. J. Pharmacol. 40(3):373-80 (1986).
Nussberger, et al., “Repeated Administration of the Converting Enzyme Inhibitor Cilazapril to Normal Volunteers”, J. Cardiovasc. Pharmacol. 9(1):39-44 (1987).
Attwood, et al., “New potent inhibitors of angiotensin converting enzyme”, FEBS Lett. 165(2):201-6 (1984).
Takata, et al., “A Comparison of the Actyivity of the Angiotensin Converting Enzyme Inhibitors SQ 14 225, SA 446 and MK 421”, Clin. Exp. Pharmacol. Physiol. 10:131 (1983).
Acta. Pharmacol. Toxicol. 59 (Supp. 5):1:224 (1986).
Acta. Pharmacol. Toxicol. 59 (Supp. 5):2:342 (1986).
Sybertz, et al., “Angiotensin-Converting Enzyme Inhibitory Activity of SCH 31846, a New Non-Sultbydryl Inhibitor”, J. Cardiovasc. Pharmacol. 5(4):643, 655 (1983).
Lees, “The Haemodynamic and Humoral Effects of Treatment for One Month with the Angiotensin Converting Enzyme Inhibitor Perindopril in Salt Replete Hypertensive Patients”, Eur. J. Clin. Pharmacol. 31(5):519-24 (1987).
Kim, et al., “(Mercaptopropanoyl)indoline-2-carboxyliAc cids and Related Compounds as Potent Angiotensin Converting Enzyme Inhibitors and Antihypertensive Agents”, J. Med. Chem. 26:394-403 (1983).
Baum, et al., “Antihypertensive Activity of SCH 31846, a Non-Sulfhydryl Angiotensin-Converting Enzyme Inhibitor”, J. Cardiovasc. Pharmacol. 5(4):655 (1983).
Davies et al., Br. J. Clin. Pharm (1984), 18, 215S-229S, submitted herewith, p. 215S-216S.
Elung-Jensen et al., Eur J Clin Pharmacol, 2005, 61:87-96.

Affiliated with

Also associated with

Rating

Compositions and methods for treatment of inflammatory bowel... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for treatment of inflammatory bowel..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of inflammatory bowel... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4314343